Hai Zheng Pharmaceutical: Publicly transferring 100% equity of its wholly-owned subsidiary, Provincial Pharmaceutical Company, at a price of 500 million yuan.

Haizheng Pharmaceuticals announced that the company has signed a stock transfer agreement and supplemental agreement with Guangzhou Pharmaceuticals, with a transfer price of 500 million RMB. This transaction is a public listing transfer, with a listed base price of 430 million RMB, and Guangzhou Pharmaceuticals successfully delisted. The transaction still needs to be reviewed by the company's shareholders' meeting and by China's anti-monopoly review agency for operator concentration review. After the transaction is completed, the provincial pharmaceutical company will no longer be included in the company's consolidated financial statements.